Rare Kidney Diseases Treatment Market (Drug Class: Enzyme Replacement Therapy, Monoclonal Antibodies, and Others)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global rare kidney diseases treatment market size was valued at USD 2.75 billion in 2022 and is predicted to be worth USD 4.88 billion by 2032, with a CAGR of 5.90% from 2023 to 2032. 

Key Pointers:

• In terms of drug class, the enzyme replacement therapy segment accounted for significant market share in 2022.
• Based on indication, the Fabry disease segment is projected to account for major share of the industry during the forecast period. 
• In terms of distribution channel, the hospital pharmacies segment is likely to account for significant share during the forecast period. 
• As per global rare kidney diseases treatment market forecast, North America accounted for the largest share of around 45% in 2021.
• Asia Pacific is anticipated to be the fastest growing region for rare kidney diseases treatment during the forecast period. 

Of the 150 different rare kidney diseases, majority are inherited. Each uncommon kidney disease has a unique set of symptoms; however, these rare diseases could collectively present overlapping diagnostic and therapeutic difficulties.

Small number of affected people, unknown disease causes, lack of biomarkers for diagnosis, and requirement of complex care are the key obstacles during diagnosis and treatment of these diseases. Rare kidney diseases are also known as rare urinary diseases. Rare kidney diseases include Fabry disease, atypical hemolytic uremic syndrome, lupus nephritis, nephropathic cystinosis, renal nutcracker syndrome, and others. Polycystic kidney disease (PKD) is a rare genetic kidney disease, in which clusters of cysts develop primarily within kidneys, resulting in an increase in size of the kidney.

Treatments for rare urinary diseases include enzyme replacement therapy, monoclonal antibodies, and others. Renal nutcracker syndrome is a rare vein compression disorder. It mostly affects left renal (kidney) vein. Symptoms of this disease include flank pain and blood in the urine. Increase in incidence of kidney diseases and rise in awareness among the people are the other factors driving market progress. Surge in geriatric population is likely to augment the global rare kidney diseases treatment market share in the near future.

The burden of various rare kidney diseases is expected to rise significantly across the globe in the next few years. Kidney-related problems, such as Fabry disease, atypical hemolytic uremic syndrome, lupus nephritis, nephropathic cystinosis, renal nutcracker syndrome, polycystic kidney disease (PKD), distal renal tubular acidosis, and IgA nephropathy disease, have increased.

Several rare kidney diseases remain untreated, which could cause serious health issues in future. According to the World Health Organization, the Fabry disease is estimated to affect approximately 1 in 40,000 men and around 1 in 20,000 women in the U.S. As per the National Organization for Rare Disorders, Inc., the incidence rate of atypical hemolytic uremic syndrome is 2 individuals per 1 million among the general population in the country.

Rare kidney diseases treatment Market Segmentation

Rare kidney diseases treatment Market Key Players And Regions